HONG KONG, March 14, 2025 /PRNewswire/ -- Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Kerry Pharma's extensive logistics (fourth-party logistics, 4PL) distribution capabilities, this collaboration aims to enhance Teva's pharmaceutical distribution system in Hong Kong, Macau, and the Greater Bay Area, ensuring a stable supply of high-quality medical products. This initiative not only strengthens Teva's presence in Hong Kong, Macau, and the Greater Bay Area, enhancing product distribution system resilience and driving quality and efficiency improvements in the regional pharmaceutical industry, but also marks a crucial step in building an efficient, transparent, and sustainable pharmaceutical supply model that prioritizes patient care.
Medicine commercial distribution stability remains a key focus in the healthcare sector. As a global pharmaceutical leader, Teva is dedicated to ensuring the safe, efficient, and reliable delivery of medicines. Under this collaboration, Kerry Pharma will serve as Teva's exclusive service provider in Hong Kong and Macau, leveraging its 4PL fulfilment solutions to establish a distribution network covering over 3,000 delivery points, including hospital pharmacies, clinics, drug stores and key chain channels. Through end-to-end pharmaceutical logistics solutions, the partnership will optimize inbound logistics, warehousing, distribution, billing, reporting and exports, ensuring operational efficiency and swift market responsiveness.
Theodor Wee, General Manager of Teva Greater China, said, "The stable supply of medicines is crucial to patient health, and Teva is always committed to exploring innovative initiatives to improve patient access to medicines continuously. This collaboration also exemplifies Teva's global 'Pivot to Growth' strategy. In the future, we will accelerate to bring more medicines that will meet the evolving needs of patients. Teva looks forward to partnering with Kerry Pharma to promote medical integration and innovation in Hong Kong, Macau, and the Greater Bay Area, leveraging each other's strengths as a model of cooperation."
Samuel Lau, Managing Director - Integrated Logistics Asia of KLN, said, "Kerry Pharma has been deeply involved in the healthcare product distribution sector, dedicated to delivering efficient, safe, and compliant integrated logistics solutions. Teva's trust, and support have enabled us to fully leverage our expertise in 4PL fulfilment solutions and multi-temperature storage. We are committed to ensuring the standards of safety and compliance throughout the delivery process, providing strong support for pharmaceutical distribution in the local market."
With the implementation of the digitalized system, Kerry Pharma has enabled data visibility for Teva, optimizing inventory forecasting and enhancing market responsiveness. Meanwhile, Kerry Pharma maintains strict temperature controls, accommodating storage requirements from 15-25°C for general pharmaceuticals to 2-8°C for sensitive items, ensuring complete cold chain integrity for all products. Additionally, building on the synergistic advantages of the ports, Kerry Pharma offers ocean freight and air freight for deliveries to Macau and the Greater Bay Area, equipped with cold chain solutions to safeguard product quality.
The partnership has already delivered promising results, with precise management of over 190 SKUs, improved supply chain efficiency and enhanced delivery timeliness. Looking ahead, Teva and Kerry Pharma will continue to explore innovative collaboration models, jointly facilitating the efficient introduction of Teva's global innovative medicines into the Greater Bay Area through policy such as the "Hong Kong and Macao Drug and Medical Device Transit". Simultaneously, by leveraging digital technologies, Teva and Kerry Pharma will enhance market demand trend forecasting and optimize resource allocation capabilities, establishing a more precise pharmaceutical distribution management system, accelerating the commercialization of Teva's innovative medicines in the Greater Bay Area and other regions across China.
Upholding the purpose "We Are all in for Better Health", Teva remains committed to providing safer and more timely supply of medicines for patients across regions. In the future, Teva will continue to explore policy integration models, partnering with industry allies to establish a more innovative, efficient, and inclusive pharmaceutical ecosystem—creating greater healthcare benefits for patients across the Greater Bay Area.
About Teva
Teva (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we're already working to address it.
Teva China has offices in Shanghai, Beijing, and Hong Kong. Teva China has established strong collaboration with partners across various sectors to enhance the product accessibility and affordability.
To learn more about how Teva is all in for better health, visit www.tevapharm.com.
About Kerry Logistics Network Limited (KLN)
KLN (Stock Code 0636.HK) is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.
With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world's emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.
KLN generated a revenue of over HK$47.4 billion in 2023. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
